Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Non Operating Income (2016 - 2025)

Sunshine Biopharma's Non Operating Income history spans 12 years, with the latest figure at $57458.0 for Q4 2025.

  • For Q4 2025, Non Operating Income rose 106.87% year-over-year to $57458.0; the TTM value through Dec 2025 reached $273286.0, up 241.12%, while the annual FY2025 figure was $273286.0, 289.16% up from the prior year.
  • Non Operating Income reached $57458.0 in Q4 2025 per SBFM's latest filing, down from $65355.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $946747.0 in Q4 2021 to a low of -$4.9 million in Q1 2021.
  • Average Non Operating Income over 5 years is -$436419.1, with a median of $86870.0 recorded in 2022.
  • Peak YoY movement for Non Operating Income: crashed 8580.13% in 2021, then skyrocketed 1442.82% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $946747.0 in 2021, then tumbled by 91.06% to $84599.0 in 2022, then skyrocketed by 86.13% to $157464.0 in 2023, then tumbled by 631.45% to -$836848.0 in 2024, then surged by 106.87% to $57458.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Non Operating Income are $57458.0 (Q4 2025), $65355.0 (Q3 2025), and $74655.0 (Q2 2025).